论文部分内容阅读
目的观察英夫利西单抗(类克)治疗难治性类风湿性关节炎(RA)的疗效及安全性。方法选取近两年我院门诊和病房确诊的难治性活动期RA患者36例,且均经甲氨蝶呤(MTX)治疗3个月无效,入选研究组后改用类克治疗,3个月后评价疗效。比较治疗前后临床疗效参数BASDAI、BASM、IESR、CRP下降情况。结果类克治疗后6周、12周临床疗效参数较治疗前显著下降(P<0.01),36例患者中1例出现输液反应,无严重不良反应发生。结论类克治疗类风湿性关节炎,效果显著,安全性较好,具有良好的临床应用前景。
Objective To observe the efficacy and safety of infliximab in the treatment of refractory rheumatoid arthritis (RA). Methods Thirty-six patients with refractory active RA diagnosed in clinic and ward in our hospital in recent two years were selected and all were treated with methotrexate (MTX) for 3 months. After treatment, After evaluation of efficacy. Before and after treatment, the clinical efficacy parameters BASDAI, BASM, IESR, CRP decreased. Results After 6 weeks and 12 weeks of treatment, the clinical curative parameters decreased significantly (P <0.01). One case of 36 patients had infusion reaction and no serious adverse reaction occurred. Conclusion Gram-type treatment of rheumatoid arthritis, the effect is significant, safety is good, with good clinical application prospects.